-
公开(公告)号：US08420335B2
公开(公告)日：2013-04-16
申请号：US12282485
申请日：2007-03-14
申请人： Paul Cloos , Karl Agger , Jesper Christensen , Klaus H. Hansen , Kristian Helin
发明人： Paul Cloos , Karl Agger , Jesper Christensen , Klaus H. Hansen , Kristian Helin
CPC分类号： C12Q1/48 , G01N33/6875 , G01N2333/91011 , G01N2500/00 , Y10T436/10
摘要： The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry.
摘要翻译： 本发明提供了测试化合物与Jumonji蛋白的JMJD2亚家族蛋白质结合并任选调节其活性的能力的方法。 该方法包括将测试化合物与Jumonji蛋白的JMJD2亚族蛋白质的蛋白质，所述蛋白质的辅因子和任选的脱甲基化底物一起孵育。 本发明的方法可用于筛选大量化合物以鉴定作为临床用于治疗某些癌症，特别是前列腺癌的候选化合物的一组化合物。 在筛选测定中不具有活性的其它化合物可以从作为候选化合物的进一步考虑中消除。 因此，本发明的方法在制药工业中具有效用。
-
公开(公告)号：US20110111023A1
公开(公告)日：2011-05-12
申请号：US12675314
申请日：2008-09-10
IPC分类号： A61K9/48 , C07K14/415 , A61K9/00 , A61K38/16 , A61P3/10
CPC分类号： A61K38/168
摘要： The invention herein is related to intranasal or other mucosal administration of gliadin, or parts thereof, to prevent the development of type 1 diabetes. This environmental antigen, which may have etiological role in the development of diabetes in genetically predisposed individuals, has been successfully applied in the prevention of disease.
摘要翻译： 本文的发明涉及鼻粘膜或其他粘膜施用麦醇溶蛋白或其部分，以防止1型糖尿病的发展。 这种可能在遗传易感个体发生糖尿病中具有病因作用的环境抗原已成功应用于预防疾病。
-
33.发明授权Compounds useful in the diagnosis and treatment of pregnancy-associated malaria 有权可用于妊娠相关疟疾诊断和治疗的化合物公开(公告)号：US07745580B2
公开(公告)日：2010-06-29
申请号：US10543312
申请日：2003-12-30
申请人： Thor Grundtvig Theander , Ali Salanti , Lars Hviid , Trine Staalsø , Anja Tatiana Ramstedt Jensen , Thomas Lavstsen , Madelaine Dahlbäck
发明人： Thor Grundtvig Theander , Ali Salanti , Lars Hviid , Trine Staalsø , Anja Tatiana Ramstedt Jensen , Thomas Lavstsen , Madelaine Dahlbäck
CPC分类号： C07K16/205 , A61K38/00 , Y10S435/975
摘要： The present invention relates to nucleic acid molecules related to the var2csa gene family as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to chondroitin sulphate A (CSA) in the placenta which is characteristic for the pathogenesis of pregnancy associated malaria (PAM). Accordingly, The invention provides the use compounds that are related to VAR2CSA polypeptides var2csa nucleic acid molecules as medicaments, as well as it provides pharmaceutical compositions, in particular immunological compositions and vaccines, hereunder nucleotide-based vaccines comprising these compounds. In addition, the invention provides the use of the compounds mentioned for the manufacture of compositions, such as immunogenic compositions. Other aspects of the invention relates to methods of treatment and prevention of pregnancy associated malaria wherein these methods are based on the nucleic acid molecules and polypeptides the invention. As these compounds can also be used as biotechnological tools the invention provides in vitro diagnostic methods and kits comprising reagents and IgGs/antibodies designated to the use in such methods. The invention also relates to methods of identifying agents capable of modulating the VAR2CSA dependent adhesion to CSA and agent capable of interacting with VAR2CSA. Finally, a method for identifying polypeptides, which will induce a specific IgG/antibody response upon administration to a subject is provided by the invention.
摘要翻译： 本发明涉及与var2csa基因家族有关的核酸分子，以及由这些核酸分子编码的氨基酸序列，涉及它们在介导感染的红细胞与胎盘中的硫酸软骨素A（CSA）的粘附中的作用， 是怀孕相关疟疾（PAM）发病机制的特征。 因此，本发明提供了与VAR2CSA多肽var2csa核酸分子作为药物相关的用途化合物，以及其提供药物组合物，特别是免疫组合物和疫苗，以下包含这些化合物的基于核苷酸的疫苗。 此外，本发明提供了所述化合物用于制备组合物如免疫原性组合物的用途。 本发明的其它方面涉及治疗和预防妊娠相关疟疾的方法，其中这些方法基于本发明的核酸分子和多肽。 由于这些化合物也可用作生物技术工具，本发明提供了体外诊断方法和试剂盒，其中包括用于此类方法的试剂和IgG /抗体。 本发明还涉及鉴定能够调节VAR2CSA对CSA的依赖性粘附和能够与VAR2CSA相互作用的试剂的鉴定试剂的方法。 最后，本发明提供了鉴定多肽的方法，所述多肽在给予受试者时将诱导特异性IgG /抗体应答。
-
公开(公告)号：US10364249B2
公开(公告)日：2019-07-30
申请号：US15028558
申请日：2014-10-24
IPC分类号： C07D491/00 , C07D491/16 , C07F7/18 , C07D471/14 , C07D491/14 , C07D471/16 , C09B69/00 , G01N21/64 , C09B15/00 , C09K11/06
摘要： The present invention relates to a new class of substituted aza-triangulenium fluorescent dyes having a hydroxy group attached to an aryl as quenching group. The new substituted aza-triangulenium fluorescent dyes may be attached to a linker, conjugated to carrier molecule such as e.g. a protein, a nucleic acid, a lipid, or a saccharide, or deposited or immobilized on solid support materials. The substituted aza-triangulenium fluorescent dyes are useful for various purposes, including use in sensors for monitoring or determining the concentration of analytes, such as H+(pH), Na+, K+, Ca2+, O2, CO2, H2O2, ionic strength, redox potentials, metal ions, and metabolites.
-
公开(公告)号：US10292406B2
公开(公告)日：2019-05-21
申请号：US15280120
申请日：2016-09-29
IPC分类号： A23J1/14 , A23L11/30 , A23L33/185 , B01D15/36
摘要： A process for the manufacture of a product from a plant material comprising the steps of providing a disrupted plant material comprising
-
公开(公告)号：US10233328B2
公开(公告)日：2019-03-19
申请号：US15028600
申请日：2014-10-24
IPC分类号： C08G77/06 , C08L83/06 , G01N21/80 , C08L83/04 , C09B67/00 , G01N21/78 , C09B11/12 , C09B57/00 , C09B69/00 , C09B69/10 , C08G77/08 , C08G77/14 , G01N21/77 , B01L3/00
摘要： The present invention relates to a method for the production of a sol-gel based matrix. The method comprises the steps of: a) providing a first alkoxysilane of the general formula: R1—Si(OR2)3 and a second alkoxysilane of the general formula (I): b) preparing a first sol-gel component by polymerization of the first alkoxysilane in the presence of an acid catalyst, c) preparing a second sol-gel component by polymerization of the second alkoxysilane in the presence of an Lewis acid catalyst, d) Mixing the first sol-gel component and the second sol-gel component for the preparation of a sol-gel based matrix. The above method results in a sol-gel based matrix with high stability and high porosity. The sol-gel based material may be used for the production of a composite or sensor suitable for monitoring analytes. Methods for preparing these composites or sensors are provided as well.
-
公开(公告)号：US20170013859A1
公开(公告)日：2017-01-19
申请号：US15280120
申请日：2016-09-29
IPC分类号： A23J1/14 , A23L33/185 , B01D15/36 , A23L11/30
CPC分类号： A23J1/14 , A23L11/34 , A23L11/35 , A23L33/185 , A23V2002/00 , B01D15/362 , B01D15/363
摘要： A process for the manufacture of a product from a plant material comprising the steps of providing a disrupted plant material comprising
摘要翻译： 一种用于从植物材料制造产品的方法，包括以下步骤：提供包含<10％（w / w）淀粉和<10％（w / w）油/脂质的破碎的植物材料; 将破碎的植物材料的pH调节至pH3.5或更低的值以提供酸性悬浮液; 将酸性悬浮液加热到约50℃至约80℃的温度范围内。 将产物与加热的酸性悬浮液分离。 该产物可以是蛋白质产物或非蛋白质产物。 特别地，本发明的方法提供了具有负营养价值的非蛋白质成分含量降低的蛋白质产物。
-
公开(公告)号：US09491958B2
公开(公告)日：2016-11-15
申请号：US14002604
申请日：2012-03-01
CPC分类号： A23J1/14 , A23L11/34 , A23L11/35 , A23L33/185 , A23V2002/00 , B01D15/362 , B01D15/363
摘要： The present invention relates to a process for the manufacture of a product from a plant material including the steps of providing a disrupted plant material including
摘要翻译： 本发明涉及从植物材料制造产品的方法，包括以下步骤：提供包含<10％（w / w）淀粉和<10％（w / w）油/脂质的破坏的植物材料; 将破碎的植物材料的pH调节至pH3.5或更低的值以提供酸性悬浮液; 将酸性悬浮液加热到约50℃至约80℃的温度范围内。 将产物与加热的酸性悬浮液分离。 该产物可以是蛋白质产物或非蛋白质产物。 特别地，本发明的方法提供了具有负营养价值的非蛋白质成分含量降低的蛋白质产物。
-
39.发明授权公开(公告)号：US09388389B2
公开(公告)日：2016-07-12
申请号：US13499788
申请日：2010-10-01
IPC分类号： C12N7/00 , C07K14/005 , C12Q1/18 , G01N33/569 , A61K39/00
CPC分类号： C12N7/00 , A61K39/00 , C07K14/005 , C12N2770/24222 , C12N2770/24251 , C12Q1/18 , G01N33/56983 , G01N2333/18
摘要： The present inventors developed hepatitis C virus recombinants expressing NS5A from genotype 1a, 1b, 2a, 3a, 4a, 5a, 6a or 7a in the context of a genotype 2a backbone. Additional recombinants express NS5A and the structural proteins (Core, E1 and E2), p7 and NS2 from genotype 1a, 1b, 3a, 4a, 5a, 6a or 7a in the genotype 2a backbone. Sequence analysis of the recombinants recovered after viral passage in Huh7.5 cells revealed adaptive mutations in NS5A and/or NS3. The importance of these mutations for improved growth kinetics was shown in reverse genetic studies.
摘要翻译： 在基因型2a骨架的上下文中，本发明人从基因型1a，1b，2a，3a，4a，5a，6a或7a开发了表达NS5A的丙型肝炎病毒重组体。 其他重组体在基因型2a骨架中表达NS5A和基因型1a，1b，3a，4a，5a，6a或7a的结构蛋白（核心，E1和E2），p7和NS2。 Huh7.5细胞病毒传代后回收的重组体的序列分析显示NS5A和/或NS3的适应性突变。 这些突变对改善生长动力学的重要性在反向遗传研究中显示。
-
40.发明申请公开(公告)号：US20140235576A1
公开(公告)日：2014-08-21
申请号：US14181169
申请日：2014-02-14
发明人： Lennart BUCH
IPC分类号： C07D207/16 , C07F7/18
CPC分类号： C07D207/16 , C07F7/1804
摘要： The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iGluR receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iGluR receptors.
摘要翻译： 本发明涉及式（I）化合物，其用于疾病治疗的组合和用途，或其药学上可接受的盐或溶剂合物，包括iGluR受体抑制剂的所有互变异构体，立体异构体和多晶型物，因此可用于治疗 精神疾病或神经障碍或与iGluR受体的异常活动相关的疾病或病症。
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.026 秒)
